Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.

Guerra-García P, Marshall LV, Cockle JV, Ramachandran PV, Saran FH, Jones C, Carceller F.

Pediatr Blood Cancer. 2019 Oct 16:e28011. doi: 10.1002/pbc.28011. [Epub ahead of print] Review.

PMID:
31617673
2.

The genetic signatures of pediatric high-grade glioma: no longer a one-act play.

Diaz AK, Baker SJ.

Semin Radiat Oncol. 2014 Oct;24(4):240-7. doi: 10.1016/j.semradonc.2014.06.003. Review.

3.

Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).

Bailey CP, Figueroa M, Mohiuddin S, Zaky W, Chandra J.

Bioengineering (Basel). 2018 Oct 18;5(4). pii: E88. doi: 10.3390/bioengineering5040088. Review.

4.

Management of high-grade gliomas in the pediatric patient: Past, present, and future.

Vanan MI, Eisenstat DD.

Neurooncol Pract. 2014 Dec;1(4):145-157. Epub 2014 Sep 12.

5.

Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.

Lu VM, Alvi MA, McDonald KL, Daniels DJ.

J Neurosurg Pediatr. 2018 Nov 30;23(3):308-316. doi: 10.3171/2018.9.PEDS18419.

PMID:
30544362
6.

The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Dasgupta T, Haas-Kogan DA.

Front Oncol. 2013 May 10;3:110. doi: 10.3389/fonc.2013.00110. eCollection 2013.

7.

Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.

Martinez-Velez N, Marigil M, García-Moure M, Gonzalez-Huarriz M, Aristu JJ, Ramos-García LI, Tejada S, Díez-Valle R, Patiño-García A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM.

Acta Neuropathol Commun. 2019 Apr 29;7(1):64. doi: 10.1186/s40478-019-0714-6.

8.

Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.

Salloum R, McConechy MK, Mikael LG, Fuller C, Drissi R, DeWire M, Nikbakht H, De Jay N, Yang X, Boue D, Chow LML, Finlay JL, Gayden T, Karamchandani J, Hummel TR, Olshefski R, Osorio DS, Stevenson C, Kleinman CL, Majewski J, Fouladi M, Jabado N.

Acta Neuropathol Commun. 2017 Oct 30;5(1):78. doi: 10.1186/s40478-017-0479-8.

9.

Low Grade Gliomas in Children.

Chalil A, Ramaswamy V.

J Child Neurol. 2016 Mar;31(4):517-22. doi: 10.1177/0883073815599259. Epub 2015 Aug 18. Review.

PMID:
26286938
10.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

11.

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Chen R, Cohen AL, Colman H.

Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Review.

PMID:
27334978
12.

Mutations in chromatin machinery and pediatric high-grade glioma.

Lulla RR, Saratsis AM, Hashizume R.

Sci Adv. 2016 Mar 18;2(3):e1501354. doi: 10.1126/sciadv.1501354. eCollection 2016 Mar. Review.

13.

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.

Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R.

Biomed Res Int. 2015;2015:215135. doi: 10.1155/2015/215135. Epub 2015 Sep 13. Review.

14.

Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.

Juratli TA, Qin N, Cahill DP, Filbin MG.

Pharmacol Ther. 2018 Feb;182:70-79. doi: 10.1016/j.pharmthera.2017.08.006. Epub 2017 Aug 19. Review.

PMID:
28830841
15.

Treatment of recurrent high-grade gliomas.

Wen PY, Brandes AA.

Curr Opin Neurol. 2009 Dec;22(6):657-64. doi: 10.1097/WCO.0b013e32833229e3. Review.

PMID:
19770658
16.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

17.

Signaling pathways and mesenchymal transition in pediatric high-grade glioma.

Meel MH, Schaper SA, Kaspers GJL, Hulleman E.

Cell Mol Life Sci. 2018 Mar;75(5):871-887. doi: 10.1007/s00018-017-2714-7. Epub 2017 Nov 21. Review.

18.

Molecular characteristics of pediatric high-grade gliomas.

Chamdine O, Gajjar A.

CNS Oncol. 2014 Nov;3(6):433-43. doi: 10.2217/cns.14.43. Review.

19.

Gliomas in children.

Minturn JE, Fisher MJ.

Curr Treat Options Neurol. 2013 Jun;15(3):316-27. doi: 10.1007/s11940-013-0225-x.

PMID:
23440592
20.

Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes.

Michaeli O, Tabori U.

J Korean Neurosurg Soc. 2018 May;61(3):319-332. doi: 10.3340/jkns.2018.0031. Epub 2018 May 1. Review.

Supplemental Content

Support Center